NCT05215925

A Study to Evaluate the Efficacy and Safety of HLX07 in nsqNSCLC Patients With High EGFR Expression

An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX07 (Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection) in Advanced nsqNSCLC Patients With High EGFR Expression

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Shanghai Henlius Biotech · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

An Open-label, Multicenter , Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 (Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection) in Combination with Chemotherapy or Monotherapy in Advanced Non-squamous Non-small Cell Lung Cancer (nsqNSCLC) Patients with High EGFR Expression

Conditions

• HLX07, nsqNSCLC, High EGFR Expression

Interventions

Type	Name	Description
DRUG	HLX07+carboplatin+pemetrexed	HLX07 1500mg q3w+carboplatin+pemetrexed
DRUG	HLX07+docetaxel	HLX07 1500mg q3w+docetaxel
DRUG	HLX07	HLX07 1500mg q3w

Timeline

• Start date: 2023-02-01
• Primary completion: 2023-07-15
• Completion: 2024-08-10
• First posted: 2022-01-31
• Last updated: 2022-07-06

Locations

1 site across 1 country: China